|
|
|
|
|
|
|
|
|
|
|
05.11.25 - 22:18
|
Dr. William G. Kaelin Jr. joins IQVIA Board of Directors (Business Wire)
|
|
|
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced the appointment of Dr. William G. Kaelin Jr. to its board of directors, effective today.
Dr. Kaelin is a Senior Physician-Scientist at Brigham and Women's Hospital in Boston and the Sidney Farber Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. He is also an Investigator at the Howard Hughes Medical Institute. In 2019, Dr. Kaelin was awarded the Nobel Prize in Physiology or Medicine for his groundbreaking work on oxygen sensing and the role of the von Hippel-Lindau (VHL tumor) suppressor protein. He currently serves on the board of directors of Eli Lilly and Company, where he chairs the Science and Technology Committee.
“I am very pleased to welcome Bill to our board of directors,” said Ari Bousbib, chairman and CEO, IQVIA. “Bill is a world-renowned scientist and physician with deep e...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
05.11.25 - 11:48
|
Ozempic maker Novo Nordisk cuts sales and profit forecasts again (The Guardian)
|
|
|
Downgrade comes as Danish company continues to lose ground to Mounjaro firm Eli Lilly in weight-loss drug marketThe maker of the weight-loss drugs Ozempic and Wegovy has cut its sales and profit forecasts as it continues to fall behind in the competitive market for obesity and diabetes treatments.Novo Nordisk's chief executive, Mike Doustdar, who took the reins in August, said the reduced guidance was because of “the lower growth expectations for our GLP-1 treatments”. Continue reading......
|
|
|
|
|
05.11.25 - 08:12
|
Novo Cuts Outlook Citing Lower Wegovy, Ozempic Sales (Bloomberg)
|
|
|
Novo Nordisk A/S pared its forecast for a fourth time this year, citing lower-than-anticipated sales of its blockbuster drugs Wegovy and Ozempic. The Danish drugmaker is struggling to compete with Eli Lilly & Co. in the growing market for obesity medicines. Bloomberg's Sara Sjolin reports....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
